Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Ruben J. Boado | M | - |
ArmaGen, Inc.
 ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | 20 years |
| Mathias Schmidt | M | 56 |
ArmaGen, Inc.
ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | 8 years |
| Eddie Island | M | - |
University of California
| - |
| William De La Peña | M | - |
University of California
| - |
| Elizabeth Schaffer | F | - |
University of California
| - |
| Kalyanam Shivkumar | M | 56 |
University of California
| 22 years |
| Robert Calfee | M | - |
University of California
| - |
| Chalieo Vitoorapakorn | M | 60 |
University of California
| - |
| Yun Feng Lu | M | 56 |
University of California
| 17 years |
| Gary May | M | 59 |
University of California
| 7 years |
| Kuo Chuan Tsai | M | - |
University of California
| - |
| Garrett Gomes | M | - |
University of California
| - |
| Jayson Punwani | M | - |
ArmaGen, Inc.
ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | - |
| Rohit Loomba | M | - |
University of California
| - |
| Napoleone Ferrara | M | 67 |
University of California
| - |
| Stephen Sherwin | M | 75 |
University of California
| - |
| James Chao | M | 62 |
University of California
| - |
| Judy Scotchmoor | F | - |
University of California
| - |
| Jefferson Coombs | M | - |
University of California
| - |
| Wendell Brase | M | - |
University of California
| - |
| Kira Stoll | F | - |
University of California
| - |
| Rachael Nava | F | - |
University of California
| - |
| Patricia Mizuiri | F | - |
University of California
| - |
| Cathy O'Sullivan | F | - |
University of California
| - |
| Nic Winterstorm | M | - |
University of California
| - |
| Karyn DiGiorgio | F | - |
University of California
| - |
| Gina Fleming | F | - |
University of California
| - |
| Jennifer Barnette | F | - |
University of California
| 5 years |
| Karina Edmonds | M | 53 |
University of California
| - |
| Arthur Torres | M | 77 |
University of California
| - |
| Wei Zong Huang | M | 64 |
University of California
| - |
| Stephen Brobst | M | - |
University of California
| - |
| Paul Wachter | M | 67 |
University of California
| - |
| Sanjay Jha | M | 60 |
University of California
| - |
| Edward Holmes | M | 83 |
University of California
| - |
| Michael Mussallem | M | 71 |
University of California
| - |
| George Marcus | M | 82 |
University of California
| 24 years |
| Mark S. Biestman | M | - |
University of California
| - |
| George Scangos | M | 76 |
University of California
| - |
| Barry Sholem | M | 68 |
University of California
| - |
| David S. Lee | M | 87 |
University of California
| - |
| Peter Preuss | M | - |
University of California
| 31 years |
| Robert Grant | M | 55 |
University of California
| - |
| Gary Hunt | M | 75 |
University of California
| - |
| Stuart Diamond | M | - |
University of California
| - |
| Kamil Hasan | M | 80 |
University of California
| - |
| Antoni Ribas | M | 58 |
University of California
| - |
| Laura Bushnell | F | 56 |
University of California
| - |
| Steve Nataupsky | M | - |
University of California
| - |
| Susan Siegel | F | 63 |
University of California
| - |
| Michael Drake | M | 73 |
University of California
| 4 years |
| Ronjon Nag | M | - |
University of California
| 9 years |
| Dara O'Rourke | M | - |
University of California
| - |
| Marc Brutten | M | 67 |
University of California
| - |
| Martin Heidecker | M | - |
ArmaGen, Inc.
ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | - |
| Umesh K. Mishra | M | 66 |
University of California
| 34 years |
| William A. Gardner | M | - |
University of California
| - |
| Susan Wessler | F | - |
University of California
| - |
| M. T. Clegg | M | - |
University of California
| - |
| James Schurz | M | - |
University of California
| 26 years |
| Charles W Tu | M | 72 |
University of California
| 6 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Carl D. Peterson | M | - |
University of California, Los Angeles
| 8 years |
| Donald A. Huebner | M | 78 |
University of California, Los Angeles
| 10 years |
| Robert E. Rich | M | - |
University of California, Los Angeles
| 7 years |
| Robert L. Berg | M | - |
The Pennsylvania State University
| 6 years |
| David M. Joyner | M | - |
The Pennsylvania State University
| 8 years |
| Lenny S. Smith | M | 77 |
University of California, Los Angeles
| 6 years |
| Jim Callaway | M | - |
ArmaGen, Inc.
ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | 4 years |
| George Diehr | M | - |
University of California, Los Angeles
| 5 years |
| Michael J. Wyatt | M | - |
The Pennsylvania State University
| 6 years |
| Darrel L. Williams | M | - |
The Pennsylvania State University
| 4 years |
| Kenneth David Malamed | M | - |
University of California, Los Angeles
| - |
| Stephen D. Yslas | M | 76 |
University of California, Los Angeles
| 7 years |
| Gordon J. Louttit | M | - |
University of California, Los Angeles
| 7 years |
| Roy M. Brisbois | M | - |
University of California, Los Angeles
| 7 years |
| Christopher P. Bisgaard | M | - |
University of California, Los Angeles
| 7 years |
| Terry O. Hartshorn | M | 79 |
University of California, Los Angeles
| 6 years |
| Howard Lawrence Berman | M | 83 |
University of California, Los Angeles
| 7 years |
| Arden A. Kelton | M | - |
University of California, Los Angeles
| 4 years |
| James Callaway | M | 68 |
ArmaGen, Inc.
ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | 4 years |
| Michael Allan Russell | M | 78 |
University of California, Los Angeles
| 7 years |
| Mark Canton | M | 74 |
University of California, Los Angeles
| 4 years |
| Peter Kam | M | 73 |
University of California, Los Angeles
| 4 years |
| John Montgomery Cameron | M | - |
University of California, Los Angeles
| 3 years |
| John Nichols | M | - |
The Pennsylvania State University
| 4 years |
| Anthony J. Armini | M | 86 |
University of California, Los Angeles
| 3 years |
| Pierre Donahue | M | - |
University of California, Los Angeles
| 4 years |
| Michael D. McCaffrey | M | 77 |
University of California, Los Angeles
| 4 years |
| David Richard Carmichael | M | 82 |
University of California, Los Angeles
| 3 years |
| Elliot L. Shell | M | - |
University of California, Los Angeles
| 4 years |
| Steve Kirtley | M | - |
University of California, Los Angeles
| 3 years |
| Harry Sloan | M | 74 |
University of California, Los Angeles
| 4 years |
| Steven L. Ezzes | M | - |
University of California, Los Angeles
| 4 years |
| Cynthia J. Ladd | F | 68 |
The Pennsylvania State University
| 4 years |
| William S. Ashmore | M | 76 |
University of California, Los Angeles
| 4 years |
| Robert A. Blatt | M | 83 |
University of California, Los Angeles
| 3 years |
| William Schumann | M | 74 |
University of California, Los Angeles
| 4 years |
| Charles Michael Gillis | M | 74 |
University of California, Los Angeles
| 4 years |
| Terry Stein | M | 74 |
University of California, Los Angeles
| 4 years |
| Jeff Zelik | M | - |
The Pennsylvania State University
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- William M. Pardridge
- Personal Network
